Estrella Immunopharma, Inc. (ESLA)
Largest Insider Buys in Sector
ESLA Stock Price History Chart
ESLA Stock Performance
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Insider Activity of Estrella Immunopharma, Inc.
Over the last 12 months, insiders at Estrella Immunopharma, Inc. have bought $0 and sold $0 worth of Estrella Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Estrella Immunopharma, Inc. have bought $44.68B and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 141,970 shares for transaction amount of $44.68B was made by Li Jianwei (Co‑Chief Executive Officer) on 2022‑03‑04.
List of Insider Buy and Sell Transactions, Estrella Immunopharma, Inc.
| 2022-03-04 | Co-Chief Executive Officer | 141,970 – | $314,700.00 | $44.68B | +0.90% |